Quality Control Guidelines for Clinical-Grade Human Induced Pluripotent Stem Cell Lines

In this talk, Andrew Gaffney is joined by Stephen Sullivan from the Global Alliance for iPSC Therapies (GAiT) to discuss the importance of iPSC characterization including details on industry terminology and grades of cell lines. This is followed by an overview of the GAiT initiative, including the requirements for producing therapeutics from iPS cells, why it’s important to build a holistic vision for translation, and the risks and mitigation strategies involved in creating a cell therapy.

About the Speakers

Dr. Stephen Sullivan is a program manager at the Global Alliance for iPSC Therapies (GAiT). Since 2017, Dr Sullivan has overseen operations at GAiT, supporting implementation and clinical application of therapies derived from pluripotent stem cells for the benefit of patients globally.

Dr. Andrew Gaffney completed his PhD in Pediatric Oncology from the University of Leeds, UK, where he successfully established a human embryonic stem cell disease model of Ewing’s sarcoma. Currently, Andrew works closely with renowned stem cell scientists in both industry and academia to monitor the requirements needed for establishing successful hPSC-based disease models, drug screens, and cell therapy applications, as part of STEMCELL’s Strategic Alliances.

Publish Date: June 09, 2020 Views: 0